Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EAGLE: Durvalumab +/- Tremelimumab vs SoC in SCCHN
NCT02369874Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 24
01
Overview
A Phase 3 trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by AstraZeneca. Started Sep 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02369874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369874.